Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04707313 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 628
- Enrollment target
NCT04707313 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 628 participants.
The verdict
NCT04707313, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 628 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-06882961) for the potential treatment of obesity. The study will compare the experiences of participants taking the study medicine (PF-06882961) to those of participants who take placebo (a look- alike substance that contains no active study medicine). The aim is to measure the body's response to the study medicine, including any changes in participants' body weight, waist and hip measurements, how well they tolerate the study medicine, and to measure levels of the study medicine in participants' blood. This study is seeking participants who have obesity, who do not have diabetes and who have had a stable body weight and not participated in a formal weight loss program in the 90 days before the study. The study medicine or placebo will be taken as tablets by mouth 2 times a day (1 time in the morning and 1 time in the evening). There are 3 groups of participants (called cohorts) in this study. For participants in Cohorts 1 and 2, total study participation will be about 9 months, with 15 planned study visits (14 visits to the study clinic and 1 telephone call). For participants in Cohort 3, total study participation will be about 10 months, with 21 planned study visits (12 visits to the study clinic and 9 telephone calls).
Interventions
- DRUG Placebo (Cohorts 1 and 2)
- DRUG PF-06882961 (Cohorts 1 and 2)
- DRUG Placebo (Cohort 3)
- DRUG PF-06882961 (Cohort 3)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 628 participants |
| Start Date | 2021-01-29 |
| Est. Completion | 2023-10-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04707313
The ClinicalTrials.gov registry entry for NCT04707313 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 628 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo (Cohorts 1 and 2) is the first listed.
NCT04707313 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04707313 about?
NCT04707313 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity". The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-06882961) for the potential treatment of obesity. The study will compare the experiences of participants taking the study medicine (PF-06882961) to those of participants who take placebo (a l...
What is the current status of trial NCT04707313?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 628 participants. The study started on 2021-01-29. Estimated completion is 2023-10-11.
What interventions are being tested in trial NCT04707313?
The interventions under investigation include: Placebo (Cohorts 1 and 2) (DRUG), PF-06882961 (Cohorts 1 and 2) (DRUG), Placebo (Cohort 3) (DRUG), PF-06882961 (Cohort 3) (DRUG).
Who is sponsoring clinical trial NCT04707313?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.